髄膜炎菌ワクチンの世界市場-2022-2029

市場力学

髄膜炎菌ワクチンの市場要因は、髄膜炎菌ワクチンに対する需要の増加と髄膜炎の有病率の増加です。

髄膜炎菌は髄膜炎の原因物質であり、一般的なインフルエンザのように発熱、嘔吐、頭痛を特徴とする重篤な疾患です。その後、細菌は体内を移動して急速に増殖し、最終的に血液、神経、脳に到達します。髄膜炎は、インフルエンザと同様に発熱、嘔吐、頭痛を特徴とする重篤な疾患であり、髄膜炎の原因菌は髄膜炎球菌です。その後、菌は体内を移動して急速に増殖し、最終的には血液や神経、脳に到達します。髄膜炎菌Bに対するワクチンの開発は、現代医学の分水嶺となるものです。B型髄膜炎菌は、南北アメリカ、カナダ、欧州、アジア、その他いくつかの地域で、病気の主要な原因となっています。2020年7月1日、髄膜炎菌Bワクチン（ベクセロ）と髄膜炎菌ACWYワクチン（ニメンリックス）は、IMDのリスクを高める特定の病状を持つすべての年齢の人々を対象に、NIPの開始により資金が提供されるようになりました。さらに、2020年4月24日、FDAは、2歳以上の侵襲性髄膜炎菌疾患を予防するための「メンクアドフィー髄膜炎菌（A、C、Y、W群）結合型ワクチン」の生物製剤承認申請を認可しました。したがって、髄膜炎菌ワクチンに対する需要の増加は、市場の成長を後押しすると予想されます。

髄膜炎菌ワクチンに関連する副作用は、市場成長の妨げになると予想されています。

MenACWYワクチンを接種した人の約半数が、注射した場所の発赤、注射した場所の痛み、筋肉痛、頭痛などの軽い副作用を経験しています。メノムネワクチンは、最も一般的な4種類の髄膜炎菌が含まれています。Menomuneは通常、注射部位の痛み、赤み、腫れ、圧痛、しこりを引き起こし、通常1～2日続きます。

CDCは、髄膜炎菌結合型ワクチンの接種を受けた人の約半数が、発熱、発赤、注射した場所の痛みなどの軽い副作用を経験すると報告しています。

産業分析

髄膜炎菌ワクチン市場は、アンメットニーズ、価格分析、サプライチェーン分析、規制分析など、様々な業界要因に基づく市場の詳細な分析を提供します。

COVID-19インパクト分析

パンデミックの初期段階において、多くの国がSARS-CoV-2の拡散リスクを軽減するために予防接種プログラムを停止しました。COVID-19により、多くの予防接種プログラムが中止されます。他の多くの国では予防接種プログラムは中止されなかったが、封じ込め対策によりワクチンの摂取は鈍化した（保護者は予防接種が行われているかどうかがわからず、学校の閉鎖が広まり予約も困難となった）。8カ国（米国、英国、イタリア、フランス、ドイツ、アルゼンチン、ブラジル、オーストラリア）で行われた調査によると、COVID-19のパンデミックの際、約半数の保護者が予定していた子供の髄膜炎菌ワクチンの接種予約を遅らせたりキャンセルしたりしたことが判明しました。このワクチン接種中断の主な理由は、ロックダウン規制（63%）とSARS-CoV-2への感染に対する懸念（33%）です。

世界の髄膜炎菌ワクチン市場レポートは、約45+市場データ表、40+図、180ページの構成で提供しています。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

• 市場影響要因
  • 促進要因
    • 髄膜炎菌ワクチンの需要増が市場成長の原動力になると予想されます。
  • 抑制要因
    • 髄膜炎菌ワクチンに関連する副作用は、市場成長を妨げると予想されます。
  • 機会
  • 影響分析

第5章 産業分析

• ポーターの5つの力
• アンメットニーズ
• サプライチェーン
• プライシング分析
• 規制分析

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、または将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的な取り組み
• まとめ

第7章 タイプ別

• コンジュゲートワクチン
• ポリサッカライドワクチン
• 混合ワクチン
• その他

第8章 血清型別

• MenACWY
• MenB/BC
• MenC
• MenAC
• MenA

第9章 エンドユーザー別

• 病院
• クリニック
• 予防接種センター
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A（合併・買収）分析

第12章 企業プロファイル

• Sanofi Pasteur Inc.
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Bio-Manguinhos
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Pfizer Inc.
• Bio-Med Pvt Ltd
• Serum Institute of India Ltd.
• Walvax Biotechnology Co., Ltd
• Incepta Pharmaceuticals Ltd.
• Chongqing Zhifei Biological Products Co., Ltd.

Market Overview

Meningococcal Vaccines Market is expected to grow at a high CAGR of 12% during the forecasting period (2022-2029).

Meningococcal vaccines are designed to safeguard against Neisseria meningitidis infection. Vaccines available target certain meningococcus strains such as A, B, C, W-135, and Y. On average, the vaccines provide 80 percent to 100 percent immunity for two years, with some requiring booster doses. The vaccinations could be monovalent, targeting a specific kind of meningococcus, or multivalent.

Market Dynamics

The meningococcal vaccines market factors are the increase in demand for meningococcal vaccines and the increasing prevalence of meningitis.

The increase in demand for meningococcal vaccines is expected to drive market growth.

Meningococcus is the causative agent of meningitis, a severe disease characterized by fever, vomiting, and headache, like the common flu. The bacteria then travel through the body and grow rapidly, eventually reaching the blood, nerves, and brain. Meningococcus is the causative agent of meningitis, a severe disease characterized by fever, vomiting, and headache, similar to the common flu. The bacteria then travel through the body and grow rapidly, eventually reaching the blood, nerves, and brain. Developing a vaccine against meningococcus B is a watershed moment in modern medicine. Meningococcus B is a leading cause of disease in the Americas, Canada, Europe, Asia, and several other regions. On July 1, 2020, the meningococcal B vaccine (Bexsero) and the meningococcal ACWY vaccine (Nimenrix) were funded under the NIP beginning for people of all ages with certain medical conditions that increase their risk of IMD. Furthermore, on April 24, 2020, the FDA approved a Biologics License Application for MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine to prevent invasive meningococcal disease in people aged 2 years and older. Hence, increasing demand for meningococcal vaccines is expected to boost the market growth.

The side effects associated with meningococcal vaccines are expected to hamper the market growth.

Approximately half of those who received a MenACWY vaccine experienced mild side effects, such as redness where the shot was administered, soreness in the area where the shot was administered, muscle aches, and headache. Four of the most common types of meningococcal bacteria are included in the menomune vaccine. Menomune commonly causes pain, redness, swelling, tenderness, or a lump at the injection site, usually lasting 1-2 days.

The CDC reports that roughly half of those who receive a meningococcal conjugate vaccine experience mild side effects, such as fever, redness, and pain where the shot was administered.

Industry Analysis

The meningococcal vaccines market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

COVID-19 Impact Analysis

During the early stages of the pandemic, many countries suspended immunization programs to reduce the risk of spreading SARS-CoV-2. Many vaccination programs are halted due to COVID-19. Although vaccination programs did not cease in many other countries, vaccine uptake slowed due to containment measures (parents were uncertain about whether vaccinations were taking place and experienced difficulties booking appointments with widespread school closures). According to studies conducted in eight countries (the United States, the United Kingdom, Italy, France, Germany, Argentina, Brazil, and Australia), approximately half of parents delayed or canceled a scheduled meningococcal vaccination appointment for their child during the COVID-19 pandemic. The main reasons for this vaccination disruption are lockdown regulations (63%) and concerns about contracting SARS-CoV-2 (33%).

Segment Analysis

The conjugate vaccines segment is expected to hold the largest market share in the meningococcal vaccines market.

Meningococcal conjugate (MenACWY) vaccine protects against four types of Neisseria meningitidis bacteria (serogroups A, C, W, and Y). It is appropriate for all children and teenagers aged 11 and up. Some types of MenACWY are given to younger children (as young as 8 weeks) if they are at a higher risk of contracting meningococcal disease. Conjugate vaccine technology has been used successfully in childhood vaccines to prevent other bacterial meningitis pathogens, such as vaccines against Haemophilus influenzae serotype b (Hib) and, more recently, seven- and nine-valent conjugate pneumococcal vaccines. Meningococcal conjugate vaccines against N. meningitidis serogroup C are highly effective in young children and adolescents, with few side effects.

There are currently four quadrivalent meningococcal conjugate vaccine formulations available globally. All contain MenA, MenC, MenW, and MenY capsular polysaccharides, but the type of carrier protein varies. MenACWY-D (Menactra, Sanofi Pasteur) is conjugated to diphtheria toxoid (D), MenACWY-CRM (Menveo, GSK) is conjugated to CRM, and two MenACWY-TT vaccines, Nimenrix (Pfizer) and the recently available MenQuadfi are conjugated to TT (Sanofi Pasteur). Furthermore, On 24 April 2020, the FDA approved a Biologics License Application for MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine to prevent invasive meningococcal disease in people aged 2 years and older.

Geographical Analysis

North American region is expected to hold the largest market share in the global meningococcal vaccines market.

The rising prevalence of meningitis is expected to drive up demand for meningitis vaccines, resulting in rapid market growth. Various pathogens can cause meningitis, but bacterial meningitis has the highest global burden. According to the National Meningitis Association (NMA), approximately 600-1,000 people in the United States contract meningococcal disease each year. Furthermore, preteens, teens, and young adults account for 21% of meningococcal disease cases.

Furthermore, the growing public awareness of the disease is expected to drive market growth in this region. The Meningitis Foundation of America (MFA) is a non-profit organization in the United States dedicated to providing information and support to people with personal experiences with meningitis. This foundation also aims to raise public and medical awareness about the early symptoms of meningitis. As a result, the meningococcal vaccine market is expected to grow steadily over the forecast period.

Competitive Landscape

Major key players in the meningococcal vaccines market are Bio-Manguinhos, Biomed Pvt. Ltd, GlaxoSmithKline PLC, Merck & Co., Inc., Pfizer Inc., Sanofi Pasteur Inc., Serum Institute of India Ltd., Walvax Biotechnology Co., Ltd, Incepta Pharmaceuticals Ltd., Chongqing Zhifei Biological Products Co., Ltd.

Sanofi Pasteur Inc.:

Overview:

Sanofi Pasteur is the world's largest company solely dedicated to vaccines. The vaccines division of the French multinational pharmaceutical company Sanofi is known as Sanofi Pasteur. The company's business is divided into pharmaceuticals, chemicals, vaccines, and consumer healthcare.

Product Portfolio:

MenQuadfi is a vaccine given to people aged 2 to help prevent invasive meningococcal disease (including meningitis) caused by the bacterium N meningitides serogroups A, C, W, and Y. Serogroup B disease is not prevented by MenQuadfi.

Key Developments:

On 24 April 2020, the FDA approved a Biologics License Application for MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine to prevent invasive meningococcal disease in people aged 2 years and older.

The global meningococcal vaccines market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The increase in demand for meningococcal vaccines is expected to drive market growth.
  • 4.1.2. Restraints:
    • 4.1.2.1. The side effects associated with meningococcal vaccines are expected to hamper the market growth.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces
• 5.2. Unmet Needs
• 5.3. Supply Chain
• 5.4. Pricing Analysis
• 5.5. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type Segment
• 7.2. Conjugate Vaccines*
  • 7.2.1.1. Introduction
  • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Polysaccharide Vaccines
• 7.4. Combination Vaccines
• 7.5. Others

8. By Serotype

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Serotype
  • 8.1.2. Market Attractiveness Index, By Serotype Segment
• 8.2. MenACWY*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. MenB/BC
• 8.4. MenC
• 8.5. MenAC
• 8.6. MenA

9. By End user

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.1.2. Market Attractiveness Index, By End user Segment
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Clinics
• 9.4. Vaccination Centre
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Serotype
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Serotype
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Serotype
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Serotype
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Serotype
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Sanofi Pasteur Inc.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Bio-Manguinhos
• 12.3. GlaxoSmithKline plc
• 12.4. Merck & Co., Inc.
• 12.5. Pfizer Inc.
• 12.6. Bio-Med Pvt Ltd
• 12.7. Serum Institute of India Ltd.
• 12.8. Walvax Biotechnology Co., Ltd
• 12.9. Incepta Pharmaceuticals Ltd.
• 12.10. Chongqing Zhifei Biological Products Co., Ltd.